| EN

Orencia®:Abatacept Injection

Orencia®:Abatacept Injection


Rheumatoid arthritis (RA). This product is combined with methotrexate for treating moderate to severe active rheumatoid arthritis in adults with poor efficacy under antirheumatic drugs (DMARDs), including methotrexate (MTX)[1].


Abatacept is the world’s first T-cell selective costimulatory immunomodulator in the field of rheumatic immunity. It can bind to CD80 and CD86 on the surface of antigen-presenting cells to prevent the interaction between the latter and CD28 on the T-cell surface, thus inhibiting T-cell activation, reducing its downstream inflammatory response, and then inhibiting joint injury[2].

For ACPA-positive rheumatoid arthritis patients, Orencia® has the following advantages:
(1) It is a costimulatory immunomodulator, which can inhibit the overactivation of immune cells, reduce inflammatory reaction and effectively treat rheumatoid arthritis[1].
(2) It can improve the disease activity of ACPA-positive patients and enable higher treatment response rates (such as ACR20, DAS28, EULAR response). ACPA can be used as a biomarker to predict the efficacy of Abatacept[3][4].

(3) Long-term use of Abatacept can lower the risk of infection-related hospitalization and incidence of tuberculosis with good level of safety[5][6][7][8].


[1]  Instructions for Abatacept Injection(NMPA approved version in 2020)

[2] Bonelli M, Scheinecker C. How does abatacept really work in rheumatoid arthritis[J]. Current opinion in rheumatology, 2018, 30(3): 295-300.

[3] Alemao E, Postema R, Elbez Y, et al. Clinical and Experimental Rheumatology, 2019.

[4] J. E. Gottenberg. et al. Arthritis & Rheumatology, Vol. 68, No. 6, June 2016, pp 1346–1352

[5] Chen S K, Liao K P, Liu J, et al. Arthritis Care and Research, 2020, 72(1): 9-17.

[6] Westhovens R, et al. Clin Exp Rheumatol, 2014, 32(4): 553-562.

[7] Genovese M C, et al. The Journal of rheumatology, 2012, 39(8): 1546-1554.

[8] Padovan M, et al.  Arthritis care & research, 2016, 68(6): 738-743.